. Author manuscript; available in PMC: 2013 Mar 14.

Published in final edited form as: J Antimicrob Chemother. 2008 Jul 18;62(5):1113–1117. doi: 10.1093/jac/dkn290

Table 2.

Pharmacokinetic parameters of branded and generic stavudine, lamivudine and nevirapine

Parameter	Stavudine	Lamivudine	Nevirapine
C_max (ng/mL)^a branded^b	203.5 (±127.7)	855.2 (±276.6)	8594.3 (±3699.0)
CV (%)	62.8	32.3	43.0
generic^b	210.3 (±208.4)	966.8 (±279.6)	7017.3 (±2757.8)
CV (%)	99.1	29.0	39.3
GMR (90% CI)	0.92 (0.78–1.08)	1.11 (0.95–1.30)	0.84 (0.64–1.11)
AUC_0–12 (ng·h/mL)^a branded	685.6 (±219.6)	5522.7 (±2009.8)	75 192.7 (±29 294.9)
CV (%)	32.0	36.4	38.9
generic	579.8 (±231.2)	6039.0 (±2370.8)	64 338.3 (±19 944.6)
CV (%)	39.9	39.3	31.0
GMR (90% CI)	0.83 (0.70–0.97)	1.06 (0.94–1.2)	0.88 (0.71–1.10)

GMR, geometric mean ratio; CI, confidence interval; C_max, maximum plasma concentration; AUC, area under the curve for concentration–time; CV, coefficient of variation.

Mean (±SD).

Number of samples: branded drugs (stavudine, lamivudine and nevirapine) = 110 each, generic = 112.